Acro Biomedical Reports Zero Revenue and Increased Financial Distress in Q1 2024

Company Overview:
Acro Biomedical Co., Ltd. (PINK: ACBM) is a Nevada corporation engaged in the development and marketing of nutritional products. The company's focus has been on cordyceps-related products, with no new product developments or revenue generated since December 2022.

Income Statement Highlights (three months ended March 31, 2024):

• Revenues: $0
• Operating Expenses: $10,298
• Net Loss: $(11,252), or $(0.00) per share
• Loss from Operations: $(10,298)

Key Points from Q1 2024 Financials:

• The company reported zero revenue, identical to the same period in 2023.
• Operating expenses decreased significantly from $4,003,566 in Q1 2023 to $10,298 in Q1 2024.
• Comprehensive loss reduced from $(4,004,354) in Q1 2023 to $(11,252) in Q1 2024.
• Interest expense from related parties rose slightly to $954.

Balance Sheet Insights:

• Total Assets: $50,792 (down from $58,459 in December 2023)
• Total Liabilities: $318,104 (up from $315,473 in December 2023)
• Stockholders' Deficit: $(267,312)
• Current Cash Position: $151 (down from $376 in December 2023)

Positive Aspects:

• Sharp decline in operating expenses, indicating cost-cutting measures.
• Reduction in net loss, reflecting improved cost management.

Negative Aspects:

• No revenue generated, raising concerns about business viability.
• Continued reliance on advances from minority stockholder for financing.
• Significant stockholder deficit indicating ongoing financial distress.
• Operating cash flow is negative, signaling liquidity issues.

Outlook and Risks:
Acro Biomedical is facing serious operational challenges, including lack of revenue and high dependency on a single funding source. The company's position is further complicated by its status on the OTC Market Group's Expert Market, impacting its ability to raise funds. Future viability hinges on securing new product orders and addressing ongoing operational deficiencies.